CN107582561A - 圣草次苷和七叶树苷在制备抗肿瘤药物中的用途 - Google Patents
圣草次苷和七叶树苷在制备抗肿瘤药物中的用途 Download PDFInfo
- Publication number
- CN107582561A CN107582561A CN201710838073.1A CN201710838073A CN107582561A CN 107582561 A CN107582561 A CN 107582561A CN 201710838073 A CN201710838073 A CN 201710838073A CN 107582561 A CN107582561 A CN 107582561A
- Authority
- CN
- China
- Prior art keywords
- eriocitrin
- esculiw
- antineoplastic
- purposes
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OMQADRGFMLGFJF-MNPJBKLOSA-N Eriodictioside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=C(O)C(O)=CC=2)O1 OMQADRGFMLGFJF-MNPJBKLOSA-N 0.000 title claims abstract description 33
- HDOMLWFFJSLFBI-UHFFFAOYSA-N Eriocitrin Natural products CC1OC(OCC2OC(Oc3cc(O)c4C(=O)CC(Oc4c3)c5ccc(OC6OC(COC7OC(C)C(O)C(O)C7O)C(O)C(O)C6O)c(O)c5)C(O)C(O)C2O)C(O)C(O)C1O HDOMLWFFJSLFBI-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 230000000118 anti-neoplastic effect Effects 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 23
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 17
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 17
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 17
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000178 monomer Substances 0.000 abstract description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 6
- 201000005296 lung carcinoma Diseases 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 32
- 230000002401 inhibitory effect Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 1
- 241000157280 Aesculus hippocastanum Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588214 Fraxinus chinensis subsp. rhynchophylla Species 0.000 description 1
- 241001143502 Hippocastanaceae Species 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710838073.1A CN107582561B (zh) | 2017-09-15 | 2017-09-15 | 圣草次苷和七叶树苷在制备抗肿瘤药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710838073.1A CN107582561B (zh) | 2017-09-15 | 2017-09-15 | 圣草次苷和七叶树苷在制备抗肿瘤药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107582561A true CN107582561A (zh) | 2018-01-16 |
CN107582561B CN107582561B (zh) | 2021-08-03 |
Family
ID=61046959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710838073.1A Active CN107582561B (zh) | 2017-09-15 | 2017-09-15 | 圣草次苷和七叶树苷在制备抗肿瘤药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107582561B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3609137A (en) * | 1968-05-31 | 1971-09-28 | Nattermann A & Cie | Process for the production of an aescin-rich concentrate of active material from horse-chestnut seeds |
JP2001199881A (ja) * | 2000-01-19 | 2001-07-24 | Pokka Corp | アポトーシス誘導剤 |
CN1689578A (zh) * | 2004-04-30 | 2005-11-02 | 浙江工业大学 | β-七叶皂甙钠在制备治疗白血病药物中的应用 |
CN102764327A (zh) * | 2012-08-15 | 2012-11-07 | 四川泰康药业有限公司 | 一种提取柠檬黄酮的方法 |
CN102793664A (zh) * | 2012-09-13 | 2012-11-28 | 太极集团有限公司 | 一种七叶皂苷钠微乳化注射剂及其制备方法 |
-
2017
- 2017-09-15 CN CN201710838073.1A patent/CN107582561B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3609137A (en) * | 1968-05-31 | 1971-09-28 | Nattermann A & Cie | Process for the production of an aescin-rich concentrate of active material from horse-chestnut seeds |
JP2001199881A (ja) * | 2000-01-19 | 2001-07-24 | Pokka Corp | アポトーシス誘導剤 |
CN1689578A (zh) * | 2004-04-30 | 2005-11-02 | 浙江工业大学 | β-七叶皂甙钠在制备治疗白血病药物中的应用 |
CN102764327A (zh) * | 2012-08-15 | 2012-11-07 | 四川泰康药业有限公司 | 一种提取柠檬黄酮的方法 |
CN102793664A (zh) * | 2012-09-13 | 2012-11-28 | 太极集团有限公司 | 一种七叶皂苷钠微乳化注射剂及其制备方法 |
Non-Patent Citations (11)
Title |
---|
ZABELA BERDOWSKA等: "Cytotoxic impact of phenolics from Lamiaceae species on human breast cancer cells", 《FOOD CHEMISTRY》 * |
冯遵永等: "七叶皂苷钠阻断JAK-1/STAT-1信号诱导BGC-823及AGS细胞凋亡 ", 《中药材》 * |
冯遵永等: "七叶皂苷钠阻断JAK-1/STAT-1信号诱导BGC-823及AGS细胞凋亡", 《中药材》 * |
吴子侠等: "七叶皂苷体外抗SGC-7901细胞的作用及机制研究 ", 《中国药理学通报》 * |
吴子侠等: "七叶皂苷体外抗SGC-7901细胞的作用及机制研究", 《中国药理学通报》 * |
杨慧慧等: "柚皮苷体外抗肿瘤活性及其机制研究", 《广东药学院学报》 * |
武汉医学院: "《营养与食品卫生学》", 31 July 1981, 人民卫生出版社 * |
秦伯益等: "《新药评价概论》", 30 June 1989, 人民卫生出版社 * |
邹明!100700北京等: "七叶皂甙钠抑制大肠癌HCT-8细胞生长及提高癌细胞对5-氟尿嘧啶敏感性的研究 ", 《中华消化杂志》 * |
邹明!100700北京等: "七叶皂甙钠抑制大肠癌HCT-8细胞生长及提高癌细胞对5-氟尿嘧啶敏感性的研究", 《中华消化杂志》 * |
魏金明: "《中国药学主题词表》", 31 May 2013, 中国医药科技出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN107582561B (zh) | 2021-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lambrianidou et al. | Recent advances on the anticancer properties of saffron (Crocus sativus L.) and its major constituents | |
Borrelli et al. | Effect of a propolis extract and caffeic acid phenethyl ester on formation of aberrant crypt foci and tumors in the rat colon | |
CN108078978A (zh) | 欧当归内酯a在制备肿瘤化疗药物增敏剂中的应用 | |
CN101099566B (zh) | 山窝苣素及其制备方法和用途 | |
CN105232623A (zh) | 一种青钱柳提取物在制备胃癌药物中的应用 | |
CN104957034B (zh) | 一种抑瘤功能茶树良种的选育方法 | |
CN1907277A (zh) | 短叶老鹳草素在肿瘤生长和增殖抑制剂中的应用 | |
CN105037464B (zh) | 一种大蓟黄酮类化合物及其制备方法与在制备抗肿瘤或护肝药物中的应用 | |
CN101152192B (zh) | 1,3-二-O-没食子酰基1-4,6-(S)-HHDP-β-D-吡喃葡萄糖在制备抗肿瘤药物中的应用 | |
CN107582561A (zh) | 圣草次苷和七叶树苷在制备抗肿瘤药物中的用途 | |
CN105380956B (zh) | 一种治疗白血病的含艾德拉尼的药物组合物及应用 | |
Melo et al. | Natural killer cell activity and anti-tumour effects of dehydrocrotonin and its synthetic derivatives | |
CN101805246A (zh) | 漆酚化合物,其药物组合物及其制备方法和应用 | |
CN102688228B (zh) | 含有芹菜素及芹菜素类衍生物和冬凌草甲素及冬凌草甲素类衍生物的药物组合物及其应用 | |
US20200375943A1 (en) | Cytocidal method of cancer cells selectively in human patients clinically by depletion of l-ascorbic acid, primarily, with its supplementation alternately augmenting its cytocidal effect | |
CN102441167B (zh) | 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用 | |
CN101513408A (zh) | 双胍基嘌呤环类衍生物制备提高抗癌药药效的新应用 | |
CN102440987B (zh) | 含有芹菜素及芹菜素类衍生物和青蒿素及青蒿素类衍生物的药物组合物及其应用 | |
CN105902561A (zh) | 龙须菜多糖作为抗肿瘤化疗药增效剂的应用及抗肿瘤药物 | |
CN102552245B (zh) | 含有表没食子儿茶素没食子酸酯与紫杉醇的抑制肿瘤细胞增殖的组合物 | |
CN102440994A (zh) | 灵芝酸g在肿瘤治疗中作为免疫增效剂和超抗原依赖的治疗药物的应用 | |
CN100381129C (zh) | 一种抗肿瘤的动物药及其制备方法 | |
Amrati et al. | Lipids Fraction from Caralluma Europaea (Guss.): MicroTOF and HPLC Analyses and Exploration of Its Antioxidant, Cytotoxic, Anti-Inflammatory, and Wound Healing Effects. Separations 2023, 10, 172 | |
CN106038571B (zh) | 一种含小分子靶向药物吉非替尼的药物组合物及其在制备抗肿瘤药物中的应用 | |
Attar et al. | Multifunctional role of Nobiletin in cancer chemoprevention: Multifunctional role of Nobiletin in cancer chemoprevention |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Zhimei Inventor after: Zhang Zhen Inventor after: Zhang Xiaotao Inventor after: Liu Rui Inventor after: Ma Yan Inventor before: Liu Rui Inventor before: Ma Yan |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210719 Address after: 266042 No. 127, four Liu Nan Road, Shibei District, Qingdao, Shandong Applicant after: QINGDAO CENTRAL Hospital Address before: Room 604, No. 71, Yichuan sixth village, Yichuan road street, Putuo District, Shanghai 200065 Applicant before: Liu Rui |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |